Premium
Retroviral gene transfer of interferon‐inducible protein 10 inhibits growth of human melanoma xenografts
Author(s) -
Feldman Andrew L.,
Friedl Josef,
Lans Titia E.,
Libutti Steven K.,
Lorang Dominique,
Miller Marshall S.,
Turner Ewa M.,
Hewitt Stephen M.,
Alexander H. Richard
Publication year - 2002
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.10292
Subject(s) - genetic enhancement , angiogenesis , melanoma , cancer research , in vivo , biology , interferon , chemokine , immunology , microbiology and biotechnology , gene , immune system , biochemistry
Interferon‐inducible protein 10 (IP‐10) is an immunomodulatory chemokine recently recognized to have potent antiangiogenic activity in vivo. Due to difficulties in the stability, manufacture and chronic administration of recombinant forms of endogenous antiangiogenic proteins, antiangiogenic gene therapy has emerged as a promising new form of cancer treatment. We retrovirally transduced A375 human melanoma cells with the human IP‐10 gene and injected cells subcutaneously into nude mice. IP‐10‐transduced cells also were mixed with null‐transduced cells in varying proportions before injection. In vivo growth of IP‐10‐transduced melanoma cells was markedly diminished compared to parental or null‐transduced cells ( p = 0.0002, Kruskal‐Wallis test). This growth inhibition was associated with a marked reduction in microvessel density. The degree of growth inhibition of tumors following injection of a mixed population of null‐ and IP‐10‐transduced cells was directly associated with the fraction of IP‐10‐transduced cells present. We conclude that retroviral transduction of human melanoma cells with the IP‐10 gene leads to sufficient protein secretion to inhibit angiogenesis and tumor growth. These findings suggest that IP‐10 gene therapy might be an effective therapy in patients with cancer. Published 2002 Wiley‐Liss, Inc.